Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
This study, called Brightline-1, is looking at a new medicine called brigimadlin (also known as BI 907828) for people who have advanced dedifferentiated liposarcoma. This is a type of cancer that has spread. The main aim is to see if brigimadlin can stop the cancer from growing for longer compared to a standard treatment called doxorubicin. Researchers will also look at how many people respond to the treatment, how long that response lasts, and if it helps people live longer. The study will also carefully check for any side effects and how the treatment affects quality of life. This is a large study, involving different stages, to get a clear picture of how well brigimadlin works.
At a glance
What is this study about?
This study, called Brightline-1, is investigating a new medication, brigimadlin (also known as BI 907828), for people who have advanced dedifferentiated liposarcoma. This is a type of cancer that has grown or spread beyond its original location. The study wants to find out if brigimadlin is a better treatment option than doxorubicin, which is a standard chemotherapy medicine currently used.
The main goal of the study is to see how long people taking brigimadlin live without their cancer growing or getting worse, compared to those taking doxorubicin. This is called 'progression-free survival'. The researchers will also be looking at other important things, like if the cancer shrinks (called 'objective response'), how long that shrinkage lasts, and overall how long people live. They'll also carefully monitor any side effects people experience and how the treatments affect their general well-being and daily life.
By comparing brigimadlin to a standard treatment, the researchers hope to understand if this new medicine could offer a more effective way to manage advanced dedifferentiated liposarcoma. This study is being carried out in different stages, allowing researchers to gather enough information to make clear conclusions about the potential benefits and risks of brigimadlin.
Key takeaways
- This study tests a new medicine (brigimadlin) for advanced dedifferentiated liposarcoma.
- It compares the new medicine to a standard treatment (doxorubicin).
- The main aim is to see if brigimadlin can stop cancer growth for longer.
- Researchers will also look at how treatments affect overall health and quality of life.
- Both men and women, aged 18 and over, may be eligible.
- Patient safety and well-being are closely monitored throughout the study.
Who may be eligible?
To be part of this study, you would need to be an adult, aged 18 years or older, with advanced dedifferentiated liposarcoma. This means your cancer has either spread or come back after previous treatments.
Both men and women can take part. There are other specific medical requirements that your doctor would check to make sure the study is a safe and suitable option for you.
- Are you 18 years old or older?
- Have you been diagnosed with advanced dedifferentiated liposarcoma?
- Are you able to travel to a study site for regular appointments?
- Are you willing to potentially receive either the new drug or the standard treatment?
- Are you comfortable filling out questionnaires about your health?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you will be randomly assigned to receive either the new medicine (brigimadlin) or a standard medicine (doxorubicin). This is like flipping a coin, so neither you nor your doctor can choose which treatment you get. Both medicines are given as an infusion into your vein, meaning it goes directly into your bloodstream.
You will have regular hospital visits for medical checks, blood tests, and scans to see how the treatment is working. The study will also ask you to fill out questionnaires to understand how you are feeling and if the treatment is affecting your quality of life. The total time you spend in the study will depend on how your cancer responds to the treatment, so it varies for each person. Even after finishing the treatment, you might have follow-up visits.
Potential risks and benefits
Locations (12)
- —Netherlands
- —Belgium
- —Czechia
- —Portugal
- —Spain
- —Norway
- —Sweden
- —France
- —Greece
- —Italy
- —Finland
- —Germany
Common questions
What is dedifferentiated liposarcoma?
It's a rare type of cancer that grows in soft tissues, often starting in fat cells. 'Dedifferentiated' means the cancer cells are less like normal cells and tend to grow more quickly.
What is 'advanced' cancer?
Advanced cancer means the disease has either spread to other parts of the body or has come back after initial treatments.
What does 'first line treatment' mean?
This refers to the first treatment given for a specific condition, especially when other treatments haven't been tried yet.
What is 'randomised' in a study?
It means patients are put into different treatment groups by chance, like drawing names from a hat. This helps make sure the groups are similar and the results are fair.
What is 'quality of life' in a study?
It's about how much the treatment affects your daily life, your comfort, and your overall well-being. Researchers use questionnaires to understand this.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.